ALB Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-mediated polyclonal knockout cell population derived from the A2780 ovarian carcinoma cell line. The ALB gene, encoding human serum albumin, has been disrupted via CRISPR/Cas9 to generate a heterogeneous pool of knockout cells. This polyclonal format provides a diverse population with varying editing events, enabling robust loss-of-function studies while maintaining the biological complexity of the A2780 background. The cells are suitable for investigating albumin-dependent pathways in ovarian cancer without the limitations of single-cell derived clones.
The A2780 cell line was established from ovarian endometrioid adenocarcinoma tissue of an untreated patient. It is a widely used epithelial ovarian cancer model characterized by its utility in studies of drug resistance and tumorigenesis. A2780 cells exhibit sensitivity to platinum-based agents, making them valuable for chemoresistance research. Their growth characteristics and molecular profile, including wild-type p53 status, support investigations into oncogenic signaling and therapeutic responses. The parental line serves as a well-characterized control, and the knockout derivative allows for direct comparison of albumin-dependent phenotypes.
Albumin is a multifunctional protein that maintains oncotic pressure and acts as a carrier for hydrophobic molecules, including fatty acids, hormones, and drugs. In the tumor microenvironment, albumin facilitates the transport and presentation of lysophosphatidic acid (LPA), a bioactive lipid that promotes cancer cell proliferation, migration, and survival. LPA signaling is transduced through LPA receptors, activating downstream cascades involving Src kinase and other effectors. Albumin interacts with albondin (gp60) to mediate caveolae-dependent transcytosis, and with SPARC, which modulates its uptake and influences TGF-?? bioavailability. The albumin-LPA axis intersects with oxidative stress responses and drug metabolism pathways. Upstream, ALB expression is regulated by transcription factors such as HNF-1??, C/EBP??, STAT3, and the cytokine IL-6. By eliminating endogenous albumin, this knockout model disrupts these intricate networks, allowing precise dissection of albumin??s role in ligand delivery and signal modulation.
In A2780 ovarian cancer cells, endogenous albumin production may contribute to autocrine or paracrine signaling loops that influence malignant behavior. Although A2780 cells are not hepatocytes, they express albumin at levels sufficient to impact LPA uptake and drug sensitivity. The knockout of ALB abrogates this local albumin pool, potentially reducing LPA-mediated activation of proliferative and migratory pathways, and altering cellular responses to chemotherapeutics like cisplatin. This model provides a relevant platform to study how albumin-dependent mechanisms contribute to ovarian cancer progression and treatment resistance, without the confounding effects of exogenous serum albumin that is typically present in culture media. Co-culture or conditioned media experiments can further isolate the extracellular roles of albumin derived from the tumor cells themselves.
The ALB Knockout A2780 Polyclonal Cells are designed for a range of advanced research applications. They enable in-depth investigation of the albumin-LPA signaling axis, including LPA uptake assays and analysis of downstream effects on proliferation and migration via MTT and Transwell assays. Functional studies of SPARC-albumin interactions can be performed using co-immunoprecipitation and protein localization techniques. The cells facilitate exploration of albumin??s impact on drug sensitivity, particularly to cisplatin and other agents, providing insight into mechanisms of chemoresistance. Additionally, they serve as a tool for developing and validating albumin-based drug delivery strategies in an ovarian cancer context. End-point analyses such as Western blotting and ELISA can verify knockout and assess pathway alterations. For further information, please contact Ascent Research.
